Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1651 to 1665 of 1766 results for patient safety

  1. NICE encourages further research into the effects of uterine artery embolisation compared with other procedures to treat adenomyosis, particularly for patients wishing to maintain or improve their fertility.

    embolisation compared with other procedures to treat adenomyosis, particularly for patients wishing to maintain or improve their...

    Research recommendation
    Published
    9 June 2015

  2. Autism spectrum disorder in adults: diagnosis and management (CG142)

    This guideline covers diagnosing and managing suspected or confirmed autism spectrum disorder (autism, Asperger’s syndrome and atypical autism) in people aged 18 and over. It aims to improve access and engagement with interventions and services, and the experience of care, for people with autism.

    Clinical guideline
    Last updated
    14 June 2021
    View recommendations

    Sections for CG142

  3. Clinicians should collect data on all patients undergoing focal cryoablation (including details of case selection, methods of follow-up and outcomes) for local audit. Clinicians should enter details about all patients undergoing focal therapy using cryoablation for localised prostate cancer onto the European Registry for Cryosurgical Ablation of the Prostate (EuCAP) register and review clinical outcomes locally.

    IPG423/2 Question Clinicians should collect data on all patients undergoing focal cryoablation (including details of case selection,...

    Research recommendation
    Published
    9 June 2015

  4. Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable (TA1048)

    Evidence-based recommendations on lisocabtagene maraleucel (Breyanzi) for treating relapsed or refractory large B-cell lymphoma in adults after first-line chemoimmunotherapy when a stem cell transplant is suitable.

    Technology appraisal guidance
    Published
    26 March 2025
    View recommendations

    Sections for TA1048

  5. Further research on endoscopic carbon dioxide laser cricopharyngeal myotomy for relief of oropharyngeal dysphagia could include the publication of collaborative audit data. Reports should separate outcomes for different groups of patients; in particular for patients with primary neuromuscular dysfunction alone, those with associated phargyngeal diverticula and those with dysphagia caused by radiotherapy. Outcome measures should include dysphagia scores, quality of life, long-term outcomes and the need for further treatment. All complications should be reported. NICE may update this guidance on publication of further evidence.

    Reports should separate outcomes for different groups of patients; in particular for patients with primary neuromuscular...

    Research recommendation
    Published
    6 April 2016

  6. Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (TA1055)

    Evidence-based recommendations on rucaparib (Rubraca) for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy in adults.

    Technology appraisal guidance
    Published
    16 April 2025
    View recommendations

    Sections for TA1055

  7. Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)

    Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.

    Technology appraisal guidance
    Published
    9 February 2022
    View recommendations

    Sections for TA770

  8. Antenatal care (QS22)

    This quality standard covers the routine antenatal care that women and their babies should receive during pregnancy. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    14 February 2023
    View quality statements

    Sections for QS22

  9. What is the safety and efficacy of botulinum toxin compared with (a) usual care, (b) antimuscarinics and (c) augmentation cystoplasty in people with primary cerebral conditions with lower urinary tract dysfunction?

    Recommendation ID CG148/5 Question What is the safety and efficacy of botulinum toxin compared with (a) usual care, (b) antimuscarinics

    Research recommendation
    Published
    9 June 2015

  10. Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation (TA798)

    Evidence-based recommendations on durvalumab (Imfinzi) for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults.

    Technology appraisal guidance
    Published
    22 June 2022
    View recommendations

    Sections for TA798

  11. NICE encourages further research into micropressure therapy for refractory Ménière's disease. Research studies should report long-term outcomes, in particular the need for subsequent surgical treatment.

    Any explanatory notes(if applicable) Current evidence on the safety of micropressure therapy for refractory Ménière's disease is...

    Research recommendation
    Published
    9 June 2015

  12. Further research on incisionless otoplasty should describe the precise surgical techniques used and should report both short- and long-term outcomes, including the need for further procedures.

    the evidence, which includes a very small number of patients. The evidence on efficacy and safety is inadequate both in...

    Research recommendation
    Published
    9 June 2015

  13. Epiretinal brachytherapy for wet age-related macular degeneration (AMD) should only be used in the context of research. Research studies should address whether epiretinal brachytherapy reduces the progression of wet AMD and whether it can reduce the number of injections of antivascular endothelial growth factor agents (anti-VEGF) required. Long-term outcomes should be reported.

    degeneration (AMD) is inadequate and limited to small numbers of patients. With regard to safety, vitrectomy has...

    Research recommendation
    Published
    9 June 2015

  14. NICE encourages further research into endoscopic radiofrequency ablation for Barrett's oesophagus with no dysplasia. Studies should define clearly the policies used for histological diagnosis. Outcomes should include complete resolution of Barrett's oesophagus, change and progression to low-grade dysplasia, high-grade dysplasia or cancer. All complications should be reported, particularly development of strictures. Comparative studies against surveillance would be useful.

    explanatory notes(if applicable) Current evidence on the efficacy and safety of endoscopic radiofrequency ablation for Barrett's...

    Research recommendation
    Published
    9 June 2015

  15. NICE encourages further research into intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer. Research should include randomised controlled trials, which stratify patients by risk and give adequate follow-up. They should report frequency of adverse events, patientreported outcome measures, overall and disease-free survival and quality of life.

    cancer. Research should include randomised controlled trials, which stratify patients by risk and give adequate follow-up. They should...

    Research recommendation
    Published
    12 December 2018